Cargando…

Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI

SIMPLE SUMMARY: Glioma is the most common primary brain tumour and main cause of death of those with primary brain tumours. Multiple studies have demonstrated that glioma patients with the molecular subtype of isocitrate dehydrogenase mutation (IDH mut) combined with O(6)-methylguanine-DNA methyltra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sha, Yongjian, Yan, Qianqian, Tan, Yan, Wang, Xiaochun, Zhang, Hui, Yang, Guoqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001198/ https://www.ncbi.nlm.nih.gov/pubmed/36900232 http://dx.doi.org/10.3390/cancers15051440

Ejemplares similares

A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication
por: Wei, Jingwei, et al.
Publicado: (2018)

Radiomics Profiling Identifies the Incremental Value of MRI Features beyond Key Molecular Biomarkers for the Risk Stratification of High-Grade Gliomas
por: Yang, Guoqiang, et al.
Publicado: (2022)

Multicenter DSC–MRI-Based Radiomics Predict IDH Mutation in Gliomas
por: Manikis, Georgios C., et al.
Publicado: (2021)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone
por: Tixier, Florent, et al.
Publicado: (2019)

Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma
por: Pandith, Arshad A, et al.
Publicado: (2020)

Predicting MGMT Promoter Methylation in Diffuse Gliomas Using Deep Learning with Radiomics
por: Chen, Sixuan, et al.
Publicado: (2022)

The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis
por: Zhou, Min, et al.
Publicado: (2019)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

IDH mutation-specific radiomic signature in lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2019)

Establishment of a Prediction Model Based on Preoperative MRI Radiomics for Diffuse Astrocytic Glioma, IDH-Wildtype, with Molecular Features of Glioblastoma
por: Du, Peng, et al.
Publicado: (2023)

MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion
por: Fontana, Laura, et al.
Publicado: (2016)

NI-02 THE ASSOCIATION BETWEEN (11)C-METHIONINE UPTAKE, IDH GENE MUTATION, AND MGMT PROMOTER METHYLATION IN PATIENTS WITH GRADE II AND III GLIOMAS
por: Okita, Yoshiko, et al.
Publicado: (2019)

Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis
por: Li, Yurong, et al.
Publicado: (2022)

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [(18)F]FDOPA Uptake in Primary Brain Tumors
por: Cimini, Andrea, et al.
Publicado: (2020)

Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status
por: Wang, Ke, et al.
Publicado: (2021)

Predicting IDH genotype in gliomas using FET PET radiomics
por: Lohmann, Philipp, et al.
Publicado: (2018)

The Significance of MGMT Promoter Methylation Status in Diffuse Glioma
por: Jovanović, Nikola, et al.
Publicado: (2022)

(18)F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
por: Kong, Ziren, et al.
Publicado: (2019)

Investigating the value of radiomics stemming from DSC quantitative biomarkers in IDH mutation prediction in gliomas
por: Ioannidis, Georgios S., et al.
Publicado: (2023)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting
por: Sakai, Yu, et al.
Publicado: (2020)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents
por: Kurdi, Maher, et al.
Publicado: (2021)

A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma
por: Wongsurawat, Thidathip, et al.
Publicado: (2020)

Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment
por: July, Julius, et al.
Publicado: (2020)

Radiomic study on preoperative multi‐modal magnetic resonance images identifies IDH‐mutant TERT promoter‐mutant gliomas
por: Wang, Haoyu, et al.
Publicado: (2022)

Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients
por: Yan, Jing, et al.
Publicado: (2021)

Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma
por: Malmström, Annika, et al.
Publicado: (2020)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
por: Håvik, Annette Bentsen, et al.
Publicado: (2012)

Preoperative and Noninvasive Prediction of Gliomas Histopathological Grades and IDH Molecular Types Using Multiple MRI Characteristics
por: Du, Ningfang, et al.
Publicado: (2022)

PREOPERATIVE DETERMINATION OF IDH STATUS AND GRADE IN GLIOMAS USING MRS
por: Nguyen, Thanh Binh
Publicado: (2023)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j1u67qsljj4o89ck7g24qcpsrq